Leadership Shuffle at Novo Nordisk: CEO Steps Down Amid Market Challenges
Novo Nordisk announced the resignation of CEO Lars Fruergaard Jorgensen amidst recent market challenges and fluctuating share prices. The company will conduct a search for a successor as Jorgensen continues as CEO temporarily.

Novo Nordisk, a major player in the pharmaceutical industry, revealed on Friday that its CEO, Lars Fruergaard Jorgensen, is set to resign.
The decision comes as Novo Nordisk grapples with recent market challenges, impacting its share prices since mid-2024, according to a company statement. Jorgensen will remain in his role during a transition period as the search for his successor ensues.
This leadership change is seen as a pivotal move for the company as it endeavors to stabilize and respond to current economic pressures.
(With inputs from agencies.)
Advertisement
ALSO READ
Social media inaction amplifies public perception of pharmaceutical risk
Major Investments and Legal Battles: The Latest in Health and Pharmaceuticals
Accretion Pharmaceuticals Ltd Launches IPO to Boost Expansion
Congress MLAs Demand Minister's Resignation Over Controversial Remarks
Trump sets 30-day deadline for pharmaceutical companies to lower US drug prices in executive order, reports AP.